Please login to the form below
PARP inihibitor
This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Talzenna cleared for breast cancer in Europe
Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
-
Senior Medical Writer
-
Salary TBC
-
Senior Copywriter
-
Salary TBC
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer opens AI-enabled drug discovery center in UK
- Spotlight interview: 15 minutes on PR in pharma
- Changing healthcare, one film at a time
- Faisal Ahmed joins healthcare comms agency Sudler London
- Red Consultancy appoints MD in its health division
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Wilmington Healthcare appoints new consultants
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
Quick links
Infographics
